Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

NCT02253251 · clinicaltrials.gov ↗

RECRUITING

Status

15000

Enrollment

OTHER

Sponsor class

Conditions

Cancer

Interventions

GENETIC: KRAS-variant and microRNA binding site mutation testing

Sponsor

MiraKind